{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-10-23",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "discontinued_date": "03/27/2026",
      "update_type": "New",
      "initial_posting_date": "03/27/2026",
      "package_ndc": "72607-100-00",
      "generic_name": "Tazemetostat Hydrobromide Tablet",
      "contact_info": "(855)-463-5127",
      "related_info": "Discontinuation of the manufacture of the drug product",
      "openfda": {
        "application_number": [
          "NDA211723"
        ],
        "brand_name": [
          "TAZVERIK"
        ],
        "generic_name": [
          "TAZEMETOSTAT"
        ],
        "manufacturer_name": [
          "Epizyme, Inc."
        ],
        "product_ndc": [
          "72607-100"
        ],
        "product_type": [
          "HUMAN PRESCRIPTION DRUG"
        ],
        "route": [
          "ORAL"
        ],
        "substance_name": [
          "TAZEMETOSTAT HYDROBROMIDE"
        ],
        "rxcui": [
          "2274384",
          "2274390"
        ],
        "spl_id": [
          "c4bd8d8a-22c1-4911-a9b4-7368582d8e5d"
        ],
        "spl_set_id": [
          "7db07b5f-4e22-467c-9c0a-f830b08dbb1d"
        ],
        "package_ndc": [
          "72607-100-00"
        ],
        "unii": [
          "6P89T5M073"
        ]
      },
      "update_date": "03/27/2026",
      "therapeutic_category": [
        "Oncology"
      ],
      "dosage_form": "Tablet",
      "presentation": "Tazverik, Tablet, 200 mg (NDC 72607-100-00)",
      "company_name": "Epizyme, Inc. (An Ipsen Company)",
      "status": "To Be Discontinued"
    }
  ]
}